Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.
- Revenue: $56.7M. Running result $56.7M. Licensing Royalties And Other: $37.84M. Nuvaxovid Sales: $0. Supply Sales: $18.85M.
- Cost of revenue: −$14.25M. Running result $42.45M.
- Gross profit: $42.45M. Running result $42.45M.
- Research and development: −$70.69M. Running result −$28.24M.
- Selling, general, and administrative: −$26.67M. Running result −$54.91M.
- Operating income: −$54.91M. Running result −$54.91M.
- Other income: $3.23M. Running result −$51.68M.
- Pre-tax loss: −$51.68M. Running result −$51.68M.
- Income tax expense: −$1.71M. Running result −$53.39M.
- Net loss: −$53.39M. Running result −$53.39M.
